A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma - Results of systematic literature research.

Amaral T, Nanz L, Higuita LMS, Ascierto P, Berking C, Couselo EM, Donia M, Dummer R, Gutzmer R, Haushild A, Jalving M, Lee R, Lorigan P, Marquez-Rodas I, Michelin O, Nathan P, Robert C, Schadendorf D, Sobczuk P, Flatz L, Leiter U, Garbe C (2025)

Publication Type: Journal article

Publication year: 2025

Journal

Book Volume: 215

DOI: 10.1016/j.ejca.2024.115160

Abstract

BACKGROUND: Over the past decade, PD-1-based immune checkpoint inhibitors (ICI) and targeted therapies (TT) with BRAF and MEK inhibitors transformed melanoma treatment. Both are widely used in the adjuvant setting. However, for patients with a BRAF V600 mutation, the optimal adjuvant therapy remains unclear due to the lack of head-to-head comparison studies. METHODS: We conducted a systematic review of real-world data on adjuvant therapy in stage III melanoma to determine the best option for patients with BRAF V600 mutations. Kaplan-Meier curves were generated for TT and ICI using Digitizelt software. RESULTS: Nine publications with 3625 patients were included. TT showed better relapse-free survival (RFS) at 6, 12, 24, and 36 months than ICI. A similar trend was observed for distant metastasis-free survival (DMFS), with no apparent difference in overall survival. CONCLUSION: Real-world data suggest that adjuvant TT may be associated with better RFS and DMFS in stage III BRAF V600-mutated melanoma compared to ICI.

Authors with CRIS profile

Involved external institutions

Eberhard Karls Universität Tübingen Germany (DE) Universitätsklinikum Essen Germany (DE) Maria Skłodowska-Curie Institute of Oncology / Centrum Onkologii–Instytut im. Marii Skłodowskiej-Curie w Warszawie Poland (PL) Vall d'Hebron University Hospital / Hospital Universitari Vall d'Hebron Spain (ES) Copenhagen University Hospital Denmark (DK) Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" Italy (IT) University of Manchester United Kingdom (GB) Hospital General Universitario Gregorio Marañón Spain (ES) Geneva University Hospitals / Hôpitaux universitaires de Genève (HUG) Switzerland (CH) East and North Hertfordshire NHS Trust United Kingdom (GB) Institut Gustave-Roussy France (FR) Universitätsspital Zürich (USZ) Switzerland (CH) Johannes Wesling Klinikum Minden Germany (DE) Universitätsklinikum Schleswig-Holstein (UKSH) Germany (DE) University Medical Center Groningen (UMCG) / Universitair Medisch Centrum Groningen Netherlands (NL)

How to cite

APA:

Amaral, T., Nanz, L., Higuita, L.M.S., Ascierto, P., Berking, C., Couselo, E.M.,... Garbe, C. (2025). A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma - Results of systematic literature research. European Journal of Cancer, 215. https://doi.org/10.1016/j.ejca.2024.115160

MLA:

Amaral, Teresa, et al. "A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma - Results of systematic literature research." European Journal of Cancer 215 (2025).

BibTeX: Download